Asulacrine (BioDeep_00000176272)

   

human metabolite blood metabolite


代谢物信息卡片


N-5-Dimethyl-9-((2-methoxy-4-methylsulfonylamino)phenylamino)-4-acridinecarboxamide

化学式: C24H24N4O4S (464.1518184)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC1=C2C(=CC=C1)C(=C3C=CC=C(C3=N2)C(=O)NC)NC4=C(C=C(C=C4)NS(=O)(=O)C)OC
InChI: InChI=1S/C24H24N4O4S/c1-14-7-5-8-16-21(14)27-23-17(9-6-10-18(23)24(29)25-2)22(16)26-19-12-11-15(13-20(19)32-3)28-33(4,30)31/h5-13,28H,1-4H3,(H,25,29)(H,26,27)

描述信息

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent
D004791 - Enzyme Inhibitors

同义名列表

3 个代谢物同义名

N-5-Dimethyl-9-((2-methoxy-4-methylsulfonylamino)phenylamino)-4-acridinecarboxamide; 9-[(4-methanesulfonamido-2-methoxyphenyl)amino]-N,5-dimethylacridine-4-carboxamide; Asulacrine



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Attia Afzal, Yunxi Zhong, Muhammad Sarfraz, Ying Peng, Longsheng Sheng, Zimei Wu, Jianguo Sun, Guangji Wang. Identification and characterization of in vivo metabolites of asulacrine using advanced mass spectrophotometry technique in combination with improved data mining strategy. Journal of chromatography. A. 2016 Apr; 1444(?):74-85. doi: 10.1016/j.chroma.2016.03.068. [PMID: 27040513]
  • Wenli Zhang, Guangji Wang, James R Falconer, Bruce C Baguley, John P Shaw, Jianping Liu, Hongtao Xu, Esther See, Jianguo Sun, Jiye Aa, Zimei Wu. Strategies to maximize liposomal drug loading for a poorly water-soluble anticancer drug. Pharmaceutical research. 2015 Apr; 32(4):1451-61. doi: 10.1007/s11095-014-1551-8. [PMID: 25355460]
  • Srinivas Ganta, James W Paxton, Bruce C Baguley, Sanjay Garg. Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. International journal of pharmaceutics. 2009 Feb; 367(1-2):179-86. doi: 10.1016/j.ijpharm.2008.09.022. [PMID: 18848873]
  • R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals. 2008 Jul; 36(7):1385-405. doi: 10.1124/dmd.108.020479. [PMID: 18426954]
  • Srinivas Ganta, James W Paxton, Bruce C Baguley, Sanjay Garg. Development and validation of bioanalytical method for the determination of asulacrine in plasma by liquid chromatography. Journal of pharmaceutical and biomedical analysis. 2008 Jan; 46(2):386-90. doi: 10.1016/j.jpba.2007.09.025. [PMID: 17981420]
  • D Fyfe, F Raynaud, R E Langley, D R Newell, G Halbert, C Gardner, K Clayton, P J Woll, I Judson, J Carmichael. A study of amsalog (CI-921) administered orally on a 5-day schedule, with bioavailability and pharmacokinetically guided dose escalation. Cancer chemotherapy and pharmacology. 2002 Jan; 49(1):1-6. doi: 10.1007/s00280-001-0389-z. [PMID: 11855748]
  • I G Robertson, B D Palmer, J W Paxton, G J Shaw. Differences in the metabolism of the antitumour agents amsacrine and its derivative CI-921 in rat and mouse. Xenobiotica; the fate of foreign compounds in biological systems. 1992 Jun; 22(6):657-69. doi: 10.3109/00498259209053128. [PMID: 1441589]
  • J W Paxton, S N Kim, L R Whitfield. Pharmacokinetic and toxicity scaling of the antitumor agents amsacrine and CI-921, a new analogue, in mice, rats, rabbits, dogs, and humans. Cancer research. 1990 May; 50(9):2692-7. doi: . [PMID: 2328494]
  • P Kestell, J W Paxton, P C Evans, D Young, J L Jurlina, I G Robertson, B C Baguley. Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice. Cancer research. 1990 Feb; 50(3):503-8. doi: NULL. [PMID: 2297692]
  • J W Paxton, P C Evans, J R Hardy. The effect of cimetidine, phenobarbitone and buthionine sulphoximine on the disposition of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulphonylamino)phenylamino]- 4-acridinecarboxamide (CI-921) in the rabbit. Cancer chemotherapy and pharmacology. 1989; 23(5):291-5. doi: 10.1007/bf00292406. [PMID: 2706733]
  • J R Hardy, V J Harvey, J W Paxton, P Evans, S Smith, W Grove, A J Grillo-Lopez, B C Baguley. Phase I trial of the amsacrine analogue 9-[( 2-methoxy-4-[(methylsulfonyl)amino]-phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921). Cancer research. 1988 Nov; 48(22):6593-6. doi: NULL. [PMID: 3180070]
  • P Kestell, J W Paxton, I G Robertson, P C Evans, R A Dormer, B C Baguley. Thiolytic cleavage and binding of the antitumour agent CI-921 in blood. Drug metabolism and drug interactions. 1988; 6(3-4):327-36. doi: 10.1515/dmdi.1988.6.3-4.327. [PMID: 3271644]
  • J W Paxton, J R Hardy, P C Evans, V J Harvey, B C Baguley. The clinical pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulfonylamino)phenylamino]-4 -acridinecarboxamide (CI-921) in a phase 1 trial. Cancer chemotherapy and pharmacology. 1988; 22(3):235-40. doi: 10.1007/bf00273417. [PMID: 3409457]
  • I G Robertson, P Kestell, R A Dormer, J W Paxton. Involvement of glutathione in the metabolism of the anilinoacridine antitumour agents CI-921 and amsacrine. Drug metabolism and drug interactions. 1988; 6(3-4):371-81. doi: 10.1515/dmdi.1988.6.3-4.371. [PMID: 3271646]
  • G J Finlay, W R Wilson, B C Baguley. Cytokinetic factors in drug resistance of Lewis lung carcinoma: comparison of cells freshly isolated from tumours with cells from exponential and plateau-phase cultures. British journal of cancer. 1987 Dec; 56(6):755-62. doi: 10.1038/bjc.1987.284. [PMID: 3435703]
  • J W Paxton, P C Evans, R M Singh. Dose-dependent pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methylsulphonylamino)phenylamino]- 4-acridinecarboxamide (CI-921) in rabbits. Cancer chemotherapy and pharmacology. 1987; 20(1):13-5. doi: 10.1007/bf00252952. [PMID: 3621447]
  • P Frank, R F Novak. Effects of anthrapyrazole antineoplastic agents on lipid peroxidation. Biochemical and biophysical research communications. 1986 Nov; 140(3):797-807. doi: 10.1016/0006-291x(86)90704-7. [PMID: 3778486]
  • J W Paxton, J L Jurlina. Comparison of the pharmacokinetics and protein binding of the anticancer drug, amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenyl-amino] -4-acridinecarboxamide in rabbits. Cancer chemotherapy and pharmacology. 1986; 16(3):253-6. doi: 10.1007/bf00293987. [PMID: 3754493]
  • W R Grove, L W DeLap, A J Grillo-López. CI-921: an analog of amsacrine with experimental activity against solid tumors. Investigational new drugs. 1986; 4(2):113-8. doi: 10.1007/bf00194589. [PMID: 3755424]
  • J L Jurlina, J W Paxton. Determination of N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenylamino]-4 -acridinecarboxamide in plasma by high-performance liquid chromatography. Journal of chromatography. 1985 Aug; 342(2):431-5. doi: 10.1016/s0378-4347(00)84539-9. [PMID: 3840491]